TABLE OF CONTENTS 1.0 EXECUTIVE SUMMARY 3 1.1 CURRENT ACTIVITIES 3 1.2 IMMEDIATE FUTURE ACTIVITIES 3 1.3 VISION 4 1.4 MISSION STATEMENT 4 1.5 COMPANY GOALS AND OBJECTIVES 4 1.6 BUSINESS PHILOSOPHY 4 2.0 SITUTATION ANALYSIS 5 2.1 GENERAL COMPANY DESCRIPTION 5 2.2 MARKET SUMMARY 6 2.2.1 MARKET TRENDS 6 2.2.2 MARKET GROWTH 6 2.2.3 MARKET DEMOGRAPHICS 6 2.2.4 TECHNOLOGICAL FORCES 6 2.2.5 POLITICAL LEGAL REGULATIONS 7 2.3 SWOT ANALYIS
Words: 3078 - Pages: 13
DECEMBER 21, 2012 CORPORATES RATING METHODOLOGY Global Pharmaceutical Industry Summary This rating methodology explains Moody’s approach to assessing credit risk for companies in the pharmaceutical industry globally. This document is intended to provide general guidance that helps companies, investors, and other interested market participants understand how key qualitative and quantitative risk characteristics are likely to affect rating outcomes for companies in the pharmaceutical industry
Words: 13613 - Pages: 55
limit of foreign ownership from 40% to 51%. Colonel Eli Lilly founded Eli Lilly and Company in 1876. It was a world leader in injectable antibiotics and in supplying insulin. Ranbaxy in early 1990¶s was India¶s largest manufacturer of bulk drugs and generic drugs. Ranbaxy approached Lilly to supply certain active ingredients or sourcing of intermediate products to Lilly in order to provide low cost sources of intermediate pharmaceutical ingredients. Success of Joint Venture i) Lilly used Ranbaxy¶s help
Words: 603 - Pages: 3
innovative medicines in all major therapeutic areas like gastro-intestinal, oncology, pain management, cardiovascular, dermatology, diabetes, etc. DRL operates in three business segments- Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products. Its Indian manufacturing operations were strengthened by acquiring American Remedies Ltd and this acquisition made Reddy’s the third
Words: 4430 - Pages: 18
INDIAN MARKET Due to poor sanitation conditions, infectious (acute) diseases are predominant in India. However, the incidence of chronic ailments, characterised by prolonged exposure, has been increasing with the emergence of lifestyle diseases in India, due to changing work pattern of the working population, higher stress levels, and unhealthy eating habits. Key issues answered through this analysis: What are acute and chronic ailments? What is the proportion of drugs for each segment in
Words: 12248 - Pages: 49
1970's industry showed major development but a strong regulatory controls also came into existence with this development, and this regulatory controls had removed the rule of permanent patent to some fixed period which resulted in birth of branded generics. ENVIRONMENTAL FORCES
Words: 2941 - Pages: 12
Product Liability and Legal Ramifications Christopher M. Branch MBA 5861 New Product Marketing 08/13/2013 Christopher Branch MBA 5861 Term 1A Dr. David Castle 08/13/2013 Product Liability and Legal Ramifications The next time you walk into a retail store like Wal-Mart, Target, Home Depot, Office Depot, Babies R’ Us/Toy R’ Us, you will see a board, typically in plain sight of the viewing public, with sheets of papers titled “Product Recall” or Safety Recall or something of the like
Words: 3293 - Pages: 14
“Beximco Pharma aspires to become a nationally admired and globally reputed generic pharmaceutical company, committed to enhancing human health and life.” Annual Report 2010 Beximco Group Mission Each of our activities must benefit and add value to the common wealth of our society.We firmly believe that, in the final analysis we are accountable to each of the constituents with whom we interact, namely: our employees, our customers, our business associates, our fellow citizens and our
Words: 11101 - Pages: 45
THE PHARMACEUTICAL MARKET: INDIA - REVIEW The Indian pharmaceutical market is highly competitive and remains dominated by low-priced, domestically-produced generics. Despite having the second largest population in the world and a growing middle class with high healthcare expectations, India accounts for less than 2% of the world pharmaceutical market in value terms. In one of the world's better performing economies, spending on pharmaceuticals accounts for less than 1% of GDP and average per
Words: 578 - Pages: 3
also little by little becoming stronger and many of the big players were going through M&A processes that further increased the sales concentration in few companies. These companies had a hard time competing with local laboratories that produced generic drugs with no R&D expenses and at a fraction of the price. Eli Lilly Ranbaxy portraits the example of the traditional JV in which Ranbaxy, a company from less-industrialized country, offered the knowledge and distribution infrastructure of the local
Words: 1256 - Pages: 6
